ACCC | FDA Approves Blinatumomab for 72- and 96-Hour Infusion Durations
FDA Approves Blinatumomab for 72- and 96-Hour Infusion Durations
On December 17, the US Food and Drug Administration approved blinatumomab for 72- and 96-hour infusion durations to offer more flexibility for physicians and their patients.
In Person Conference & ConventionSeptember 22, 2026 at 5:00 PM CDT1500 Park Pl Blvd, Minneapolis, MN, USADoubleTree by Hilton Hotel Minneapolis - Park Place, Minneapolis
In Person Conference & ConventionOctober 3, 2026 at 7:30 AM EDT8787 Keystone Crossing, Indianapolis, IN, USASheraton Indianapolis Hotel at Keystone Crossing, Indianapolis
